Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
assess the activity and toxicity of second-line treatment with pazopanib after failure of
first-line sunitinib treatment in patients with clear cell mRCC; to investigate the potential
association of DLL4, Notch1, VEGFA, PDGFRB, HIF-1α and HIF-2α with clinical response to
pazopanib in mRCC patients.